Etid klinik pou Obèsite nan Maryland
53 etid pou Obèsite ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyiMande peman pou patisipan yo
Laj 19 a 85 · Tout sèks · Mizajou Oct 2, 2026 · NCT01927783Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteVolontè an sante akeyi
Laj 21 a 75 · Fanm · Mizajou Oct 2, 2026 · NCT03288207Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 1 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT01143454New Heart Imaging Techniques to Evaluate Possible Heart Disease
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT01399385A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- Endo and Metabolic Consultants, Rockville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07564414A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Barry J. Reiner, MD LLC, Baltimore
Ap rekriteFaz 3
Laj 8 a 18 · Tout sèks · Mizajou Sep 30, 2026 · NCT07253285Physical and Behavioral Traits of Overweight and Obese Adults
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT00428987Diabetes and Heart Disease Risk in Blacks
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Sep 28, 2026 · NCT00001853A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Ascension Saint Agnes Heart Care, Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07595549A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Beltsville
- Research Site, Oxon Hill
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07776509Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Capital Digestive Care - Chevy Chase, Chevy Chase
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Johns Hopkins Children's Center, Baltimore
Ap rekriteFaz 3
Laj 6 a 17 · Tout sèks · Mizajou Sep 24, 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Capital Digestive Care - Chevy Chase, Chevy Chase
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Centennial Medical Group, Columbia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Centennial Medical Group, Columbia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Beltsville
- Research Site, Lanham
- Research Site, Oxon Hill
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07784270A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Flourish Research - Bowie, Bowie
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07369011Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Ascension Saint Agnes Heart Care, Baltimore
- MD Medical Research, Oxon Hill
- Velocity Clinical Research - Rockville, Rockville
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- MedStar Good Samaritan Hospital, Baltimore
- MedStar Health Research Institute (MedStar Physician Based Research Network), Hyattsville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07321886Children s Growth and Behavior Study
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyiMande peman pou patisipan yo
Laj 8 a 100 · Tout sèks · Mizajou Sep 21, 2026 · NCT02390765Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate
- National Institutes of Health Clinical Center, Bethesda
Ap rekrite
Laj 18 a 65 · Tout sèks · Mizajou Sep 18, 2026 · NCT06044935A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
- Research Site, Brooklyn
Ap rekriteFaz 1Volontè an sante akeyi
Laj 35 a 75 · Fanm · Mizajou Sep 17, 2026 · NCT07013643Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 12 a 25 · Tout sèks · Mizajou Sep 17, 2026 · NCT06730113A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Bowie
- AURORA-1 Clinical Site, Rockville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Bowie
- AURORA-2 Clinical Site, Rockville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743450A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
- Research Site, Brooklyn
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 55 · Tout sèks · Mizajou Sep 16, 2026 · NCT07723833Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Ascension Saint Agnes Heart Care, Baltimore
- Johns Hopkins University, Baltimore
- Metropolitan Cardiovascular Consultants LLC, Beltsville
- ak 1 plis
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 16, 2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Centennial Medical Group, Columbia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351058A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Baltimore VA Medical Center, Baltimore
- Johns Hopkins University School of Nursing, Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Silver Spring
Ap rekriteFaz 3Volontè an sante akeyi
Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
- Research Site, Brooklyn
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 9, 2026 · NCT07511205A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
- PAREXEL Intl - EPCU-Baltimore, Baltimore
Ap rekriteFaz 1
Laj 18 a 55 · Tout sèks · Mizajou Sep 9, 2026 · NCT07566390Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
- Johns Hopkins University, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06847399A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Dermatology and Skin Cancer Specialists, LLC, Rockville
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Annapolis
- Kailera Clinical Site, Columbia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284901Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Columbia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284875A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Ascension Saint Agnes Heart Ca, Baltimore
- Mercy Medical Center, GI Research, Baltimore
- Flourish Research Bowie, Bowie
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07567001Evaluation of Children With Endocrine and Metabolic-Related Conditions
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
3 Months – 100 Years · Tout sèks · Mizajou Aug 13, 2026 · NCT02769975Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Silver Spring
Ap rekriteFaz 3
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change
- National Institutes of Health Clinical Center, Bethesda
Ap rekrite
Laj 18 a 50 · Tout sèks · Mizajou Jul 31, 2026 · NCT06325722Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.